Jump to main content
Jump to site search


Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches

Abstract

Neuropsychiatric disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Depression, have seriously put much inconvenience on the life of patients. Growing evidence indicates that these diseases are closely related to the monoamine oxidase (MAO) enzyme, making it an attractive target for the exploitation of potent MAO inhibitors (MAOIs) with high selectivity and low side effects. Although various MAOIs have been discovered, the discovery of an ideal MAOIs is not an easy task. In this review, we discussed nowadays available rational design strategies for obtaining ideal MAOIs including ligand-based design strategy and receptor-based design strategy, and these strategies with the aid of specific examples from the recent literature were further illustrated. To better understanding the biological activity, we also highlight the binding modes of typical inhibitors against MAO. Besides, advanced strategies for finding upcoming potent MAOIs were prospected.

Back to tab navigation

Publication details

The article was received on 05 Sep 2018, accepted on 22 Nov 2018 and first published on 24 Nov 2018


Article type: Review Article
DOI: 10.1039/C8MD00446C
Citation: Med. Chem. Commun., 2018, Accepted Manuscript
  •   Request permissions

    Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches

    X. Li and R. Hong, Med. Chem. Commun., 2018, Accepted Manuscript , DOI: 10.1039/C8MD00446C

Search articles by author

Spotlight

Advertisements